Literature DB >> 9234549

Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques.

D H Fuller1, M M Corb, S Barnett, K Steimer, J R Haynes.   

Abstract

In contrast to results obtained with plasmid DNA vectors encoding antigens from viruses such as influenza and hepatitis B, plasmids coding for antigens from primate immunodeficiency viruses have elicited relatively weak antibody responses following gene gun-mediated DNA immunization of rhesus monkeys. In an effort to augment these responses, the importance of the immunization schedule was investigated, as well as the possible synergy that might result from boosting gene gun-primed animals with other routes of immunization. Here we demonstrate that endpoint gp120-specific antibody titers can be enhanced as much as tenfold by reducing the number of immunizations and lengthening the resting period between immunizations. In addition, boosting gene gun-primed animals with either recombinant subunits or gp120-expressing vaccinia recombinants resulted in synergistic responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234549     DOI: 10.1016/s0264-410x(96)00271-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

Review 1.  Combination DNA plus protein HIV vaccines.

Authors:  Shan Lu
Journal:  Springer Semin Immunopathol       Date:  2006-09-21

2.  Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines.

Authors:  K Anwer; K A Earle; M Shi; J Wang; R J Mumper; B Proctor; K Jansa; H C Ledebur; S Davis; W Eaglstein; A P Rolland
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

3.  Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates.

Authors:  M J McCluskie; C L Brazolot Millan; R A Gramzinski; H L Robinson; J C Santoro; J T Fuller; G Widera; J R Haynes; R H Purcell; H L Davis
Journal:  Mol Med       Date:  1999-05       Impact factor: 6.354

4.  Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.

Authors:  Kristopher Kolibab; Amy Yang; Steven C Derrick; Thomas A Waldmann; Liyanage P Perera; Sheldon L Morris
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

Review 5.  DNA and RNA-based vaccines: principles, progress and prospects.

Authors:  W W Leitner; H Ying; N P Restifo
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

6.  Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.

Authors:  T Hanke; R V Samuel; T J Blanchard; V C Neumann; T M Allen; J E Boyson; S A Sharpe; N Cook; G L Smith; D I Watkins; M P Cranage; A J McMichael
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

7.  Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors.

Authors:  L Hanlon; D Argyle; D Bain; L Nicolson; S Dunham; M C Golder; M McDonald; C McGillivray; O Jarrett; J C Neil; D E Onions
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.

Authors:  N A Doria-Rose; C Ohlen; P Polacino; C C Pierce; M T Hensel; L Kuller; T Mulvania; D Anderson; P D Greenberg; S-L Hu; N L Haigwood
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates.

Authors:  Peter T Loudon; Eric J Yager; Debbie T Lynch; Amithi Narendran; Cristy Stagnar; Anthony M Franchini; James T Fuller; Phil A White; Julia Nyuandi; Clayton A Wiley; Michael Murphey-Corb; Deborah H Fuller
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

10.  Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.

Authors:  Jukka Hartikka; Vesselina Bozoukova; Jane Morrow; Denis Rusalov; Mark Shlapobersky; Qun Wei; Sou Boutsaboualoy; Ming Ye; Mary K Wloch; John Doukas; Sean Sullivan; Alain Rolland; Larry R Smith
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.